Analyzing NLS Pharmaceutics (NASDAQ:NCEL) & Inotiv (NASDAQ:NOTV)

Inotiv (NASDAQ:NOTV) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Inotiv and NLS Pharmaceutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inotiv	1	0	1	0	2.00
NLS Pharmaceutics	1	0	1	0	2.00

Inotiv currently has a consensus target price of $1.50, suggesting a potential upside of 8,326.97%. NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 489.74%. Given Inotiv’s higher probable upside, equities research analysts plainly believe Inotiv is more favorable than NLS Pharmaceutics.

Institutional & Insider Ownership

18.2% of Inotiv shares are held by institutional investors. 7.8% of Inotiv shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Inotiv and NLS Pharmaceutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inotiv	$507.36 million	0.00	-$68.62 million	($2.53)	-0.01
NLS Pharmaceutics	N/A	N/A	-$8.30 million	N/A	N/A

NLS Pharmaceutics has lower revenue, but higher earnings than Inotiv.

Profitability

This table compares Inotiv and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inotiv	-17.14%	-56.77%	-8.91%
NLS Pharmaceutics	N/A	N/A	N/A

Volatility and Risk

Inotiv has a beta of 3.77, suggesting that its stock price is 277% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Summary

NLS Pharmaceutics beats Inotiv on 5 of the 9 factors compared between the two stocks.

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.